Revolution Medicines, Inc. (RVMD) Stock
RVMD has an Alpha Score of 62 out of 100 (moderate), computed on Aug 29, 2026 from 3 of 4 sub-scores. 7 of the hedge funds AlphaScala tracks reported RVMD in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $110.48M. Company insiders reported 0 open-market buys and 79 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
What is RVMD's Alpha Score?
How it works →Alpha Score of 62 reflects moderate overall profile with strong momentum, strong value, weak quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Aug 29, 2026 · 54 days ago; due for a rescore
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own RVMD?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 590K | $110.48M | +47% |
| Duquesne Family Office Stanley Druckenmiller | 400K | $74.83M | +27% |
| Marshall Wace | 245K | $45.80M | +13% |
| Millennium Management Israel Englander | 216K | $40.49M | -43% |
| Point72 Steve Cohen | 60K | $11.29M | NEW |
| D.E. Shaw David Shaw | 12K | $2.32M | -99% |
| Blackstone | 10K | $1.80M | +172% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Revolution Medicines, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 29, 26 | Sandler Alan B. | Chief Development Officer | SELL | 2.2K | $442K |
| Sep 29, 26 | Sandler Alan B. | Chief Development Officer | SELL | 1.6K | $325K |
| Sep 29, 26 | Sandler Alan B. | Chief Development Officer | SELL | 1.0K | $203K |
| Sep 29, 26 | Sandler Alan B. | Chief Development Officer | SELL | 1.2K | $244K |
| Sep 29, 26 | Sandler Alan B. | Chief Development Officer | SELL | 301 | $62K |
| Sep 25, 26 | Mancini Anthony | See Remarks | SELL | 3.1K | $626K |
| Sep 25, 26 | Cislini Jeff | SVP & General Counsel | SELL | 765 | $159K |
| Sep 24, 26 | Mancini Anthony | See Remarks | SELL | 587 | $117K |
| Sep 22, 26 | Anderson Elizabeth M | Director | SELL | 910 | $175K |
| Sep 22, 26 | Anderson Elizabeth M | Director | SELL | 5.0K | $960K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →What are RVMD's key statistics?
Key statistics as of Oct 21, 2026
How does RVMD's valuation compare with the Healthcare sector?
| Metric | RVMD | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -2833.88% | 9.40% | 92 |
| Return on equity | -54.06% | 11.24% | 99 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Oct 22, 2026). P/E excludes loss-making companies.
RVMD price chart
Powered by TradingViewWhat does Revolution Medicines, Inc. do?
Revolution Medicines is a late-stage clinical oncology company focused on developing targeted therapies for cancers driven by the RAS protein, one of the most common cancer drivers affecting approximately 30% of human cancer diagnoses. Founded in 2014 and headquartered in Redwood City, California, the company applies its proprietary RAS(ON) chemistry platform to create small-molecule inhibitors that target the active form of the RAS protein. The company's lead candidate, daraxonrasib, is advancing through multiple global Phase 3 trials for metastatic pancreatic ductal adenocarcinoma and non-small cell lung cancer, targeting multiple oncogenic RAS variants simultaneously. Revolution Medicines' pipeline also includes selective RAS(ON) inhibitors such as zoldonrasib for RAS G12D-mutant cancers and elironrasib for RAS G12C-selective applications. The company operates as a pre-commercial entity with no approved products, generating value through its high-throughput drug discovery platform and strategic partnerships designed to advance precision oncology therapies that move beyond earlier-generation RAS inhibitors.